| Non-Small Cell Lung Carcinoma
Lumakras vs Tagrisso
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Lumakras vs Tagrisso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTagrisso has a higher rate of injection site reactions vs Lumakras based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tagrisso but not Lumakras, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lumakras
Tagrisso
At A Glance
Oral
Once daily
KRAS G12C inhibitor
Oral
Daily
EGFR kinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily as a single agent until disease progression or unacceptable toxicity.
Metastasis from malignant neoplasm of colon and/or rectum 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily in combination with panitumumab until disease progression or unacceptable toxicity; administer the first dose prior to the first panitumumab infusion.
Adjuvant Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 3 years.
Locally advanced, unresectable (Stage III) Non-Small Cell Lung Carcinoma Following platinum-based chemoradiation therapy, 80 mg orally once daily until disease progression or unacceptable toxicity.
First-line metastatic Non-Small Cell Lung Carcinoma (monotherapy) 80 mg orally once daily until disease progression or unacceptable toxicity.
First-line locally advanced or metastatic Non-Small Cell Lung Carcinoma (combination) 80 mg orally once daily in combination with pemetrexed and platinum-based chemotherapy until disease progression or unacceptable toxicity.
Previously treated EGFR T790M mutation-positive metastatic Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) - NSCLC Diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, cough.
Most common (>=20%) - mCRC with panitumumab Rash, dry skin, diarrhea, stomatitis, fatigue, musculoskeletal pain.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, pneumonia, diarrhea (NSCLC); sepsis, intestinal obstruction (mCRC with panitumumab).
Most common (>=20%) Diarrhea, rash, musculoskeletal pain, nail toxicity, dry skin, stomatitis, fatigue.
Serious ILD/pneumonitis, QTc interval prolongation, cardiomyopathy, keratitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, aplastic anemia.
Postmarketing Erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, erythema dyschromicum perstans, aplastic anemia.
Pharmacology
KRAS G12C inhibitor; sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS, thereby blocking tumor cell growth and promoting apoptosis in KRAS G12C tumor cell lines.
Osimertinib is a kinase inhibitor that irreversibly binds to mutant EGFR forms (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type EGFR, inhibiting tumor cell proliferation in EGFR mutation-positive NSCLC; it also inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lumakras
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tagrisso
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Lumakras
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Tagrisso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Lumakras
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tagrisso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LumakrasView full Lumakras profile
TagrissoView full Tagrisso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.